Intelligence Platform
Patents
Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 6268384
Compounds possessing neuronal activity
expired patentUS 6268352
Promoters of neural regeneration
expired patentUS 6268350
Polynucleotides for inhibiting metastasis and tumor cell growth
expired patentUS 6268348
Synthetic compounds and compositions with enhanced cell binding
expired patentUS 6265380
Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
expired patentUS 6265214
Methods and compositions for inducing monocyte cytotoxicity
expired patentUS 6265192
Glycosly sulfortransferase-3
expired patentUS 6265175
Method for production of neuroblasts
expired patentUS 6264957
Product of infectious respiratory syncytial virus from cloned nucleotide sequences
expired patentUS 6264952
Method for protecting a mammalian host against infection by Brucella
expired patentUS 6266622
Nuclear receptor ligands and ligand binding domains
expired patentUS 6265564
Expressed ligand-vascular intercellular signalling molecule
expired patentUS 6265563
Opioid receptor genes
expired patentUS 6264970
Sustained-release preparation
expired patentUS 6265539
Prophylaxis and therapy of acquired immunodeficiency syndrome
expired patentUS 6265160
Method of identifying inhibitors of the Jak-Stat signal transduction pathway
expired patentUS 6262242
Tumor suppressor designated TS10Q23.3
expired patentUS 6262336
Expression of a heterologous protein C in mammary tissue of transgenic animals using a lon
expired patentUS 6262335
Transgenic mice expressing APP mutant at amino acids 717, 721 and 722
expired patentUS 6262283
Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of amino
expired patentUS 6262267
Thienopyridine compound
expired patentUS 6262257
Calixpyrroles, calixpyridinopyrroles and calixpyridines
expired patentUS 6262244
DNA and amino acid sequence specific for natural killer cells
expired patentUS 6261535
Diagnostic methods for targeting the vasculature of solid tumors
expired